Wellington Management Group’s NewAmsterdam Pharma NAMS Stock Holding History

Wellington Management Group’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.41M	Sell	218,749 -4,897,069	-96%	-$161M	﹤0.01%	1376
2026 Q1	$164M	Buy	5,115,818 +82,643	+2%	+$2.69M	0.03%	428
2025 Q4	$177M	Buy	5,033,175 +1,013,049	+25%	+$36.9M	0.03%	415
2025 Q3	$114M	Buy	4,020,126 +697,129	+21%	+$16.7M	0.02%	529
2025 Q2	$60.2M	Sell	3,322,997 -218,978	-6%	-$3.99M	0.01%	639
2025 Q1	$72.5M	Buy	3,541,975 +1,226,852	+53%	+$27.3M	0.01%	586
2024 Q4	$59.5M	Buy	2,315,123 +2,222,900	+2,410%	+$47.2M	0.01%	661
2024 Q3	$1.53M	Buy	92,223 +9,162	+11%	+$159K	﹤0.01%	1621
2024 Q2	$1.6M	Sell	83,061 -135,021	-62%	-$2.71M	﹤0.01%	1568
2024 Q1	$5.16M	Buy	+218,082	New	+$4.43M	﹤0.01%	1313

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Wellington Management Group's NAMS Position: Q2 2026 in Review

Wellington Management Group reduced its NewAmsterdam Pharma (NAMS) stake by 96% in Q2 2026, selling an estimated $161M and leaving 218,749 shares worth $7.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Wellington Management Group first reported a position in NAMS in Q1 2024 and has held it in 10 quarters since. The position peaked at $177M in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Wellington Management Group held 218,749 shares of NewAmsterdam Pharma worth $7.41M as of Q2 2026.
Wellington Management Group sold 4,897,069 NewAmsterdam Pharma shares in Q2 2026, an estimated $161M.
NewAmsterdam Pharma made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1376 holding.
Wellington Management Group first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 10 quarters since.
Wellington Management Group's NewAmsterdam Pharma position peaked at $177M in Q4 2025.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.